Clinicians treating patients with hepatitis C who did not respond to first-line direct acting antivirals (DAA) treatment should delay re-treating if possible, until new “salvage” therapies arrive in Australia. This was the message delivered by infectious diseases and hepatitis specialist Associate Professor Mark Douglas at GESA’s Australian Gastroenterology Week 2017. The various DAA combinations now available on the PBS ...
Hopes pinned on hepatitis C “salvage” combos
By Tessa Hoffman
22 Aug 2017